Date Title  
Jan 27, 2023
Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings
 
Jan 27, 2023
Summary ToggleSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 Million
 
Nov 10, 2022
Summary ToggleSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
 
Oct 03, 2022
Summary ToggleSol-Gel Technologies Appoints Michael Glezin Vice President, Business Development
 
Aug 04, 2022
Summary ToggleSol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
 
Jun 02, 2022
Summary ToggleGalderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of Rosacea
 
Jun 01, 2022
Summary ToggleSol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare Conference
 
May 17, 2022
Summary ToggleSol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment Conference
 
May 13, 2022
Summary ToggleSol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
 
Apr 25, 2022
Summary ToggleSol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
 
Displaying 1 - 10 of 93 results